Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
B06AX08
|
| gptkbp:brand |
Pyrukynd
|
| gptkbp:CASNumber |
1350545-91-7
|
| gptkbp:chemicalFormula |
C24H25N3O3S2
|
| gptkbp:developer |
gptkb:Agios_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
mitapivat
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
pyruvate kinase activator
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache back pain |
| gptkbp:target |
gptkb:pyruvate_kinase_(PKLR)
|
| gptkbp:usedFor |
gptkb:anemia
pyruvate kinase deficiency |
| gptkbp:bfsParent |
gptkb:PYRUKYND
|
| gptkbp:bfsLayer |
6
|